BCVA can partially work in a virtual setting with validated digital tools and telemedicine oversight, but usually still benefits from a controlled, in-person environment. OCT essentially requires on-site or mobile-hub execution, since its equipment and image-quality requirements aren't feasible on consumer devices. IOP can be measured remotely, but only for select, stable patients with specialized equipment such as rebound tonometers. For most ophthalmic endpoints, a hybrid model, not a fully virtual one, is what actually holds up to regulatory scrutiny.
Why Does Trial Model Choice Affect Diversity and Access?
Traditional clinical trials often struggle to recruit participants from diverse backgrounds, since taking time off work or simply reaching the trial location can be genuine barriers for minority communities. Remote and hybrid trial options exist specifically to address that gap.
Virtual clinical trials are a form of decentralized research that let participants complete assessments, visits, and follow-ups remotely, reducing or eliminating travel to a traditional investigational site. Data collection occurs through mobile health apps, wearable devices, patient diaries, and other electronic patient-reported outcomes, all of which are subject to source data verification. Virtual trials can run fully remote, with no clinic visits at all, or as part of a hybrid model that combines some in-person visits with virtual elements. Mobile hub options add a third path, bringing the trial site closer to the patient rather than requiring the patient to travel.
The model chosen has a real effect on who ends up enrolled. African Americans make up only 15% of minority participants in clinical trials, and Hispanics make up only 7.6%. The FDA has identified this gap as a serious challenge to drug development and broader medical progress, and is actively encouraging more innovative, patient-centric trial strategies to close it. Virtual and hybrid trials tend to be more efficient than fully traditional trials, and real-time data collection can yield clearer results that don't rely solely on scheduled appointments.
Can BCVA Be Measured in a Fully Virtual Clinical Trial?
Best-corrected visual acuity can be measured as part of a virtual trial, but it requires validated digital tools that deliver real-time results and meet regulatory requirements, with instructions standardized and available in multiple languages. Telemedicine oversight is necessary, and data must be collected in appropriate locations, since BCVA results are sensitive to lighting and testing distance, and data capture needs to be sufficiently detailed to capture that variability.
There's a lot that can go wrong in an uncontrolled home setting, which is why BCVA benefits from site visits or mobile vision clinics. Hybrid options offer a controlled environment with calibrated equipment and certified technicians who can verify data before it's submitted. For primary endpoints specifically, a hybrid design is usually the most appropriate choice.
Can OCT Be Performed Virtually?
For OCT, a fully virtual trial simply doesn't work. The equipment requires specialized training and calibration given its complexity, and the high-resolution data requirements, capturing images and transmitting large amounts of information in real time, aren't feasible on most smartphones or consumer devices. Patients also struggle to position themselves correctly at home, which skews results, and there's no established set of virtual protocols for OCT to fall back on.
Hybrid options solve this without forcing a trade-off. Patients participate without facing some of the burdens of a fully traditional study, while reliable data collection stays intact, since having technicians on-site means accurate grading and consistent images every time.
Can IOP Be Measured Remotely?
Fully remote, decentralized trials can support IOP assessment, but only for select patients. It requires training patients on equipment such as rebound tonometers, and generally works best with patients managing stable conditions like glaucoma. That data can offer meaningful information for interventions and drug development when it works.
For broader use, mobile or on-site models offer more consistency and regulatory confidence, since IOP assessment benefits from the kind of controlled environment a Mobile Vision Clinic can reliably provide.
How Do Sponsors Manage Data Quality, Consistency, and Risk Across Models?
Data quality is the central concern across every model. On-site or mobile hub options need certified technicians so there's never a question about how information was gathered, along with standardized environments: consistent lighting, distance, and equipment calibration are what reduce variability and produce viable data. Most fully virtual trials can't match that consistency on their own, though they do offer something else valuable: real-time data from advanced digital health technology like wearables, which provides ongoing metrics traditional visit-based collection can't. Whatever the model, documentation has to be just as consistent, with calibration logs and training records thorough and traceable enough to support the endpoint.
Security and regulatory compliance are a significant part of this picture too. The FDA was among the first regulatory bodies to issue recommendations specifically for decentralized clinical trials. Data privacy is one of the more complex areas, with data minimization and pseudonymization both helping prevent patient information from being easily identified, alongside regular security audits and clear patient education on how their data will be used and protected. Informed consent has to reflect all of this directly, and electronic health record integration needs to happen without putting patient data at risk.
What Are the Benefits and Challenges of Virtual vs. Hybrid Models?
Virtual models give sponsors access to a more diverse patient population and reduce financial burden on patients, since travel isn't required to participate, which helps engagement and retention. Enrollment can move faster, letting a trial begin sooner, and it's often more cost-effective for sponsors overall. The trade-off is variability: each patient's home environment can affect data quality, and it's harder to guarantee exam windows are met or that data integrity holds consistently.
Hybrid and mobile vision clinic hub models are patient-centric in a different way, making assessments easier to access without requiring travel to a single fixed facility. Patients can go to a local mobile hub, or the clinic can come directly to their home, and because trained technicians are involved throughout, these models produce more consistent, reliable trial data. Advanced on-site equipment supports better data collection and in-person patient education, and direct patient interaction helps keep scheduling timelines on track, rather than depending on patients to self-examine correctly.
How Should Sponsors Design Trials Around Ophthalmic Endpoints?
Visit mapping: Use an endpoint-by-visit matrix to determine exactly when virtual sessions are appropriate and when they aren't. For primary endpoints, the setting should be as controlled as possible, typically by opting for an in-person visit.
Device and personnel standards: Specify the exact performance specs required from devices and equipment, along with recalibration frequency, and document precisely what training technicians must complete before performing independent assessments.
Remote monitoring and safety: Define clear remote monitoring triggers, whether risk-based, data-driven, or event-driven, and build a clear reporting pathway for adverse events or serious adverse events, including exactly when an issue should escalate to an on-site or mobile hub visit.
Patient engagement and operations: Plan when and how participants receive reminders about interventions and education, and offer real-time troubleshooting support to protect data quality throughout the study.
What Regulatory and Quality Signals Do Agencies Watch For?
Regulatory agencies evaluate virtual and hybrid trial data in specific, predictable ways. They look for validation of digital tools, confirming every tool functions as intended and meets required standards, and Good Manufacturing Practices may apply depending on the technology involved. A clear trial protocol protects every participant and gives the study team guidance no matter what circumstances arise, and endpoints need to be defined as narrowly as possible alongside a clear definition of what success looks like for that specific trial. Agencies also pay close attention to how data outliers are handled, not just whether they exist.
How Does 20/20 Onsite Enable Hybrid Ophthalmic Trials?
20/20 Onsite offers Mobile Vision Clinics and other point-of-need solutions for clinical trials, with certified staff and state-of-the-art equipment delivering BCVA, OCT, IOP, and more in a way that's convenient for both patients and sponsors. Patient-day coordination boosts retention and endpoint reliability as part of that patient-centric approach, while sponsors get site-readiness workflows and startup checklists to keep execution consistent, an approach we go into further in how sponsors and CROs should evaluate ocular endpoint execution partners.
20/20 Onsite's team serves sponsors and clinical trial sites nationwide, with insight into common concerns and the ability to accommodate diverse patient demographics in service of the research results a trial actually needs. If a trial is already struggling, clinical trial rescue services and solutions are available too.
Ready to Plan a Patient-Centric, Data-Reliable Approach?
Decentralized models can meaningfully strengthen trial execution, and hybrid options using mobile vision hubs give participants added convenience without compromising ophthalmic data quality. Some BCVA assessments can be collected at home with the right tools, but most interventions and confirmatory testing still require a controlled environment like a mobile clinic.
If you're planning your next trial or finalizing endpoints, schedule a consultation with 20/20 Onsite's team, or arrange a virtual tour of a Mobile Vision Clinic to see how it can support your study firsthand.
Frequently Asked Questions
Can BCVA testing be done in a fully virtual clinical trial? Partially. BCVA can be measured virtually with validated digital tools, standardized multilingual instructions, and telemedicine oversight, but results are sensitive to lighting and testing distance, which is why hybrid models with a controlled environment are usually the safer choice for primary endpoints.
Why can't OCT be performed in a fully virtual clinical trial? OCT requires specialized, calibrated equipment and high-resolution image capture with real-time data transmission that consumer devices can't handle. Patients also struggle to position themselves correctly without a trained technician, which skews results, and no established virtual protocol currently exists for OCT.
Can IOP be measured remotely in a decentralized trial? Yes, but only for select patients. Remote IOP measurement requires training patients on specialized equipment like rebound tonometers and works best for those managing stable conditions such as glaucoma. Broader use still benefits from the consistency and regulatory confidence of a mobile or on-site model.
What's the difference between a fully virtual and a hybrid clinical trial? A fully virtual trial doesn't require any clinic visits, relying entirely on remote data collection tools. A hybrid trial combines some in-person visits, often at a mobile hub or via a mobile vision clinic, with virtual elements, balancing patient convenience against the controlled conditions certain endpoints require.
How does trial model choice affect diversity in clinical trial enrollment? Traditional site-based trials create real barriers for minority communities, including time off work and travel access, which contributes to underrepresentation: African Americans make up only 15% of minority trial participants, and Hispanics only 7.6%. Virtual and hybrid models reduce those barriers and support more diverse enrollment.
What should sponsors document to support regulatory review of a hybrid ophthalmic trial? Validation records for every digital tool used, device performance specs and recalibration schedules, technician training documentation, clear remote monitoring triggers and adverse event reporting pathways, and a narrowly defined endpoint with a clear definition of trial success.
How does 20/20 Onsite support hybrid ophthalmic clinical trials? 20/20 Onsite provides Mobile Vision Clinics and point-of-need solutions staffed by certified technicians delivering BCVA, OCT, and IOP testing, along with patient-day coordination, site-readiness workflows, and startup checklists that help sponsors maintain consistent execution across a hybrid trial model.